April 2019

LEAP: Hormonal IUD Market Research Qualitative Findings in Kenya and Nigeria

This presentation from April 2019 outlines findings from qualitative market research in Kenya and Nigeria. Focus group discussions were held to understand perspectives about potential advantages and disadvantages of the hormonal IUD and to refine the method profile description. This analysis, authored by Routes2Results and PSI, helped create a framework for follow-on quantitative evaluations of market demand.

May 2020

LEAP: Adolescent Girls' and Young Womens' Perspectives on the Hormonal IUD in Zambia

This presentation provides an overview of the methods and findings from focus group discussions conducted among adolescent girls and young women (AGYW) in Zambia as part of the LEAP Initiative with support from the Bill & Melinda Gates Foundation.

May 2020

LEAP: Adolescent Girls' and Young Womens' Perspectives on the Hormonal IUD in Nigeria

This presentation provides an overview of the methods and findings from focus group discussions conducted among adolescent girls and young women (AGYW) in Nigeria as part of the LEAP Initiative with support from the Bill & Melinda Gates Foundation.

November 2018

LEAP Regulatory Matrix

This file is intended for use as an appendix to the LEAP Regulatory Assessment. The Regulatory Assessment can be found among regulatory resources on this site.

November 2018

LEAP Regulatory Assessment

This report, authored by WCG and FHI 360, is intended to provide both strategic analysis and technical guidance to donors, implementing organizations and hormonal IUD suppliers on pathways to increase national approvals of hormonal IUD product(s). The primary focus of the assessment was on hormonal IUD products that 1) currently have approval from a Stringent Regulatory Authority (SRA); and 2) are currently offered at an affordable public sector price in FP2020 markets. Note: This report is accompanied by an appendix tool, the Regulatory Matrix, which is also available as a regulatory resource on this site.

October 2020

ICA Foundation: Supporting LNG-IUS Access in Low- and Middle-Income Countries Brief

This research utilization and impact brief comes out of the Population Council 2019 Annual Report and highlights the ICA Foundation's efforts with the hormonal IUD. It summarizes the ICA Foundation's research, research use and impact.

October 2019

Hormonal IUD Learning Site Visits: Expanding Contraceptive Method Choice in Kenya

This report summarizes, a 2-day experiential learning site visit organized to Kisumu county to learn more about recent experiences with hormonal IUS provision in public sector settings. The site visit provided an opportunity for the national Ministry of Health, county governments and implementing partners to learn from field experiences and have an open exchange of ideas, knowledge, and implementation strategies for comprehensive FP/LARC services, including the hormonal IUS. This initiative was co-coordinated between Envision FP and MCSP.

January 2023

Evidence from Clinical Trial Data Addressing Common Misconceptions about the Hormonal IUD

Secondary analysis of the data collected through the ACCESS IUS trial, conducted by Medicines360, indicates that rigorous clinical trial data could adequately address common misconceptions about the hormonal IUD, which may be barriers to method use. These slides, originally presented at ICFP 2022, share user outcomes from the trial.

September 2020

EECO: Hormonal IUD Pilot Introduction Findings in Madagascar

This presentation from September 2020 summarizes findings from the pilot introduction of the hormonal IUS in Madagascar, conducted through a longitudinal study with IUS users and providers. The study objective was to understand user experiences and profiles, as well as IUS continuation rates.

November 2021

Cost Effectiveness Analysis of Including Hormonal IUD in the Contraceptive Method Mix in Nigeria and Zambia: Summary of Results

This analysis estimates the incremental cost-effectiveness of the hormonal IUD compared to other contraceptive methods available in Nigeria and Zambia over a 5-year and 10-year period. Separate models were built for Nigeria and Zambia reflecting the different service delivery contexts, contraceptive prevalence, and current method mix. Costs were estimated from the perspective of the health system as well as from the societal perspective.